Patents by Inventor Daniel Sebastian Christopher BUTLER

Daniel Sebastian Christopher BUTLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LON PROTEASE, ALPHA-HEMOLYSIN, CK1-ALPHA-1; C-MYB INHIBITOR OR A CEBP-DELTA INHIBITOR AS THERAPEUTICS
    Publication number: 20230055209
    Abstract: A therapeutic agent comprising Lon protease, or a variant or active fragment thereof, alpha-hemolysin, or a variant or active fragment thereof, CK1?1, or a variant or active fragment thereof, a c-MYB inhibitor and/or a CEBP-? inhibitor, for use in therapy, with the proviso that the therapeutic agent does not comprise a bacteria or bacterial supernatant. Methods of production and use thereof.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: LINNANE PHARMA AB
    Inventors: Catharina SVANBORG, Daniel Sebastian Christopher BUTLER
  • NOVEL THERAPY
    Publication number: 20200155534
    Abstract: An antagonist of Neurokinin-1 receptor (NK1R), or its ligand Substance P (SP), for use in the treatment of bacterial infections, in particular acute cystitis, or for the management of pain related to the bacterial infection. Compositions for use in this manner form a further aspect of the invention, together with methods of treatment.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 21, 2020
    Applicant: LINNANE PHARMA AB
    Inventors: Catharina SVANBORG, Daniel Sebastian Christopher BUTLER, Ines AMBITE